Navigation Links
OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
Date:2/28/2011

BOTHELL, Wash., and VANCOUVER, British Columbia, Feb. 28, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced today that Scott Cormack, OncoGenex's president and chief executive officer, will take part in a panel discussion on novel cancer treatments at the upcoming RBC Capital Markets Healthcare Conference. The panel discussion entitled, "Cancer Treatments: Under the Radar Unique Late-Stage Opportunities", will take place on Wednesday, March 2, 2011, at 9 a.m. (Eastern Time) in the Holmes I Room of the New York Palace Hotel, in New York City.

A live audio webcast of the panel discussion will be available on Investor Relations page of the OncoGenex website at www.oncogenex.com. A replay of the webcast will also be available on the Company's website for a period of 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
2. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... HOUSTON , Dec. 17, 2014 ... Autism Approved ( http://bit.ly/1382OkS ) program seal ... autism community. The program highlights medical practices, materials ... considered "autism-community friendly." Children affected by ... that can be exacerbated by ingredients found in ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Inferior Vena Cava (IVC) Filters ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sector is projected to reach US$435 million by 2016. ... nearly 39% (2015) of the global value while ...
Breaking Medicine Technology:Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4
... 27, 2011 Boca Pharmacal, Inc. announced today ... approval and commercial launch of Hydrocodone Bitartrate and ... of Victory Pharma,s Xodol®. Hydrocodone Bitartrate and Acetaminophen ... moderately severe pain (Logo: http://photos.prnewswire.com/prnh/20110127/FL37887LOGO) ...
... SILVER SPRING, Md., Jan. 27, 2011 The U.S. ... drug designation workshop for academics, biotechnology companies, and those ... 1, 2011, in Claremont, Calif. in collaboration with Keck ... The workshop, co-sponsored by the National Organization ...
Cached Medicine Technology:Fourth FDA Orphan Drug Designation Workshop Scheduled for Feb. 28 - March 1, 2011 2
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... work commitment is a big reason why, new research suggests. ... Mathias Basner, an assistant professor of sleep and chronobiology in ... A time-use survey of nearly 125,000 Americans, ages 15 ... exchanged for sleep. Short sleepers -- those who slept six ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ... on a new study providing evidence on the impact ... of children. , Sufficient enough evidence already exists showing ... or juice drinks, with the onset of tooth decay. ... drinks listed as 100% fruit juice, meaning it is ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... Kathy McAfee, America's Marketing Motivator, was announced a ... category of Best Blog 2014. McAfee received the top ... blog Networking Ahead which combines many different ... talent and influence through better networking, leadership and communication ... Ahead for Business, has been motivating readers for the ...
(Date:12/15/2014)... Ontario (PRWEB) December 15, 2014 Bacteroides is ... Not only is it much more prevalent than coliforms, it ... replicate in the environment. , Key Benefits of the ... for fecal contamination , Eliminates false positives from ... Specificity and Sensitivity , Maintain the same ...
Breaking Medicine News(10 mins):Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... , ATLANTA, Sept. 21, Webmedx ... the U.S. and a premier supplier of clinical documentation technology, ... Clinical Documentation Platform, QualityAnalytics (TM). ... abstraction for other types of queries including Medicare,s Recovery Audit ...
... LYON, France and SWIFTWATER, Pa., Sept. 21 ... and NYSE: SNY ), announced today that the company ... and Human Services (HHS) to produce vaccine to help protect against ... the production of bulk antigen equivalent to 27.3 million doses based ...
... September 21 Occlutech AG, the leading European,developer of products ... Spain IZASA SA, it defeated a request for an injunction,against ... I of Barcelona, Spain by its U.S. competitor AGA Medical. ... based on alleged patent infringement and unfair,competition claims related to ...
... New method uses risk estimation to guide management, experts say ... to determine a woman,s risk of developing cervical cancer is ... , Their proposal appears as a Keynote Comment article in ... issue of The Lancet Oncology . , Cytology (cell ...
... In simultaneous releases published around across the globe today, the World ... leading cause of lung cancer among U.S. and Canadian non-smokers. ... lower radon gas levels by one-third below the current U.S. guidance. ... needing radon control systems from 8 million to 15 million. , ...
... , , , RACINE, ... of greenhouse gas (GHG) emissions, and many companies are waiting ... forward in its quest to do the right thing and ... Earth project. , , Team ...
Cached Medicine News:Health News:Webmedx Launches New Data-Mining Solution for Medical Transcription and Speech-Generated Documents 2Health News:Sanofi Pasteur Receives Additional Order from U.S. Government to Produce Influenza A (H1N1) Vaccine 2Health News:Sanofi Pasteur Receives Additional Order from U.S. Government to Produce Influenza A (H1N1) Vaccine 3Health News:Sanofi Pasteur Receives Additional Order from U.S. Government to Produce Influenza A (H1N1) Vaccine 4Health News:Sanofi Pasteur Receives Additional Order from U.S. Government to Produce Influenza A (H1N1) Vaccine 5Health News:Researchers Propose Improved Cervical Cancer Screening 2Health News:World Health Organization Launches New Attack on Lung Cancer 2Health News:SC Johnson Joins Conservation International's Team Earth, a Worldwide Sustainability Movement, As One of the Founding Members 2Health News:SC Johnson Joins Conservation International's Team Earth, a Worldwide Sustainability Movement, As One of the Founding Members 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: